Skip to content

Our lead product for severe pneumonia, rhu-pGSN, has application for COVID19.

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS
PUBLICATIONS
CONTACT

News

Exciting news about plasma gelsolin therapy and BioAegis Therapeutics discoveries on infectious, inflammatory and degenerative diseases.

February 2019: BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study

February 1, 2019

December, 2018: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Five Granted Patents in 2018

December 15, 2018

September, 2018: BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round

September 20, 2018

June, 2018: BioAegis Therapeutics Abstract Presented at ASM-Microbe

June 19, 2018

December, 2017: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2017

December 15, 2017

November, 2017: Community Acquired Pneumonia Etiology Review in Clinical Infectious Diseases Reinforces Need for Host-Based Approach

November 15, 2017

October, 2017: BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

October 20, 2017

October, 2017: BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

October 20, 2017

Page1 Page2 Page3 Page4 Page5 … Page8

Stay informed of our latest discoveries and news.

EMAIL

GENERAL NEWS/MEDIA

June 2020: BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial

June 24, 2020

June 2020: KYW InDepth Podcast – Why NIH is Studying a NJ Lab’s COVID-19 Treatment?

June 10, 2020

May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research

May 21, 2020

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19

May 11, 2020

SCIENTIFIC PUBLICATIONS

Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza.

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia.

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

FOLLOW US

Facebook Twitter Linkedin Youtube

©2020 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use